Status:

RECRUITING

Safety and Feasibility of the ELIOS System in POAG Patients

Lead Sponsor:

Elios Vision, Inc.

Conditions:

Glaucoma, Primary Open Angle

Eligibility:

All Genders

45+ years

Phase:

NA

Brief Summary

Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG)

Eligibility Criteria

Inclusion

  • Diagnosis of mild to moderate POAG
  • Medicated IOP of \<=24 mmHg
  • Shaffer angle grade of III or IV
  • CD ratio \<=0.8
  • At least 45 years old

Exclusion

  • Closed-angle and secondary glaucomas
  • Prior incisional glaucoma surgery, intraocular surgery, or corneal surgery
  • Cannot undergo medication washout in the study eye
  • Diagnosis of degenerative visual disorders Non-study eye with BCVA worse than 20/80 Known corticosteroid responder Pregnant or nursing women; or women of childbearing potential not using medically acceptable birth control

Key Trial Info

Start Date :

October 18 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2026

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT05999006

Start Date

October 18 2023

End Date

April 1 2026

Last Update

June 17 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Elios Vision Clinical Site

Glendale, Arizona, United States, 85306

2

Elios Vision Clinical Site

Largo, Florida, United States, 33770

3

Elios Vision Clinical Site

Rock Island, Illinois, United States, 61201

4

Elios Vision Clinical Site

Oklahoma City, Oklahoma, United States, 73112